Ligand id: 6779

Name: ranibizumab

Compound class Antibody
Approved drug? Yes (FDA (2006), EMA (2007))
International Nonproprietary Names
INN number INN
8313 ranibizumab
Fab-12 variant Y0317 | Lucentis® | muMAb VEGF A.4.6.1 | rhuFab V2
Ranibizumab is a Fab fragment of a monoclonal antibody designed to target vascular endothelial growth factor A (VEGFA).
Annotated peptide sequences for this antibody derivative are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals that ranibizumab sequences are claimed in patent WO1998045331 (clone Y0317) [2], with an expected affinity similar to clone Y0313-1. It is the Fab fragment of bevacizumab.
Database Links
Specialist databases
IMGT/mAb-DB 84
Other databases
GtoPdb PubChem SID 178103385
PubChem SID 178103385
Search PubMed clinical trials ranibizumab
Search PubMed titles ranibizumab
Search PubMed titles/abstracts ranibizumab
Wikipedia Ranibizumab